Flu Season Alert!Alerta de temporada de influenza:
Don’t let germs win this season – protect yourself and your family!
The flu vaccine is your best defense against flu and related complications – PLUS, it is a covered benefit for Texas Children’s Health Plan members! Learn more!
¡No permitas que los gérmenes ganen esta temporada! ¡Protégete a ti y a tu familia!
La vacuna contra la influenza es tu mejor defensa contra la influenza y sus complicaciones. Además, ¡es un beneficio cubierto para los miembros de Texas Children's Health Plan! Aprende más
Change in Preferred Drug List Status for Antihyperuricemics Drug Class
Date: April 25, 2024
Attention: All Providers
Effective date: April 22, 2024
Call to action: Effective April 22, 2024, the Texas Health and Human Services (HHS) removed non-preferred status from brand name Mitigare products. This is in response to the discontinuation of the brand products Colcrys by the manufacturer.
The preferred status of the brand name Colcrys will not change to allow any remaining stock to be used.
How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Please see below for the list of impacted drugs (of note, the approval is NDC-specific):
Preferred Medication NDC
Preferred Medication
Type of Change
Effective Date
59467031801
MITIGARE 0.6 MG CAPSULE
Brand now preferred
April 22,2024
59467031810
MITIGARE 0.6 MG CAPSULE
Brand now preferred
April 22,2024
59467031830
MITIGARE 0.6 MG CAPSULE
Brand now preferred
April 22,2024
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
